Silver Encapsulated Magnetic Nanoparticles for Pathogen Inactivation in Platelets

银封装磁性纳米粒子用于灭活血小板中的病原体

• 批准号: 7325661
• 负责人: SEASON S-S WONG
• 金额: $ 14.54万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-15 至 2008-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7325661
• 关键词: Address; Adopted; Aerobic; Aerobic Bacteria; Affect; Alloys; American; Americas; Anaerobic Bacteria; Area; Award; Bacteria; Biochemical; Biochemistry; Biological; Biological Assay; Blood; Blood Banks; Blood Platelets; Blood donor; Burn Trauma; Businesses; Canada; Cancer Center; Cancer Patient; Capital; Carbon; Catalysis; Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chemicals; Chemistry; Client; Clinical; Collaborations; Collection; Communities; Compatible; Computers; Contractor; Data; Decontamination; Detection; Detergents; Development; Devices; Disinfection; Doctor of Medicine; Donor Selection; Dose; Economics; Educational workshop; Electronics; Emerging Technologies; Encapsulated; Ensure; Equipment; Equipment and Supplies; Equipment and supply inventories; Erythrocytes; Europe; Evaluation; Excision; Experimental Designs; Fever; Foy; Frequencies; General Population; Genetic; Goals; Government; Gram-Positive Bacteria; Grant; Growth; HIV Infections; Health; Healthcare Systems; Hepatitis B; Hospitals; Hour; Household; Housekeeping; Human; Immune system; In Vitro; Industry; Infection; Infection prevention; Intervention; Investments; Left; Legal patent; Licensing; Life; Magnetism; Marketing; Measures; Mechanics; Medical; Medical Surveillance; Medicine; Metabolic Marker; Methods; Microbe; Microbiology; Modern Medicine; Modification; Morbidity - disease rate; New York; None or Not Applicable; Nosocomial Infections; Numbers; Oxygen; Ozone; Pathologist; Patients; Persons; Phase; Pik-off; Plasma; Platelet Transfusion; Price; Principal Investigator; Process; Proteins; Public Health; Purpose; Quality of life; Quebec; Radiation therapy; Range; Rate; Reading; Reagent; Research; Research Project Grants; Residual state; Resources; Retrieval; Risk; Safety; Sales; Sampling; Savings; Scientist; Screening procedure; Seasons; Secure; Seeds; Sepsis; Series; Services; Side; Silver; Silver Compounds; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Solvents; Standards of Weights and Measures; Sterilization for infection control; Supporting Cell; Surface; Surgical incisions; System; T-Cell Leukemia; Techniques; Technology; Temperature; Testing; Texas; Time; Today; Transfusion; United States; United States Food and Drug Administration; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Viral; Virus; Water; Whole Blood; Work; antimicrobial; authority; bactericide; base; catalyst; cell growth; chemotherapy; clinically significant; college; commercialization; cost; day; design; engineering design; experience; hazard; improved; innovation; laptop; microbial; mortality; nano; nanoparticle; nanosized; nanostructured; new technology; novel; particle; pathogen; prevent; professor; programs; prototype; rapid growth; research and development; research clinical testing; seal; sensor; size; success; transmission process; ultraviolet irradiation; volunteer

DESCRIPTION (provided by applicant): The goal of this Phase I project is to demonstrate the feasibility of combining the well known and accepted antimicrobial metallic silver compound with magnetic nanoparticles and perform preliminary evaluation of its efficacy in bacterial inactivation in cellular blood product, such as platelets. Lynntech, in collaboration with M.D. Anderson Cancer Center in Houston, TX and The University of New York at Binghamton, will synthesis these silver coated magnetic nanoparticles (Ag-MP), which can be completely retrieved from platelets after the bacterial inactivation process. Our preliminary data with bacteria spiked blood platelets and broth have shown that both Gram positive and negative bacteria as well as aerobic and anaerobic bacteria can be inactivated. According to the National Blood Data Resource Center, about 13.9 million units of whole blood are donated in the United States each year. The market for blood products is over $ 10 billion and growing. With more than 90 million units of blood donated world-wide every year, the need for methods to improve the safety of blood products is truly significant. The economic impact associated with the savings from infection prevention is also enormous (when cases are considered as nosocomial infections, the estimated annual cost range from $296 million to $2.3 billion). Blood platelets are very important in modern medicine; however, they are very prone to bacterial contamination and their short-term shelf-life. Bacterial contamination of platelets is the leading cause of mobility and mortality from a transfusion-transmitted infection. Bacterial contamination rates for platelets have been estimated to occur at a frequency of 1:2,000 - 1:3,000 platelet units. The risk of receiving a bacterially contaminated platelet is 50 to 250 times higher than the combined risk of transfusion- related infections from HIV, hepatitis B and C, and human T cell leukemia (HTLV I/II) viruses. New compounds developed to counter microbial contamination in blood components have been developed and showed slight efficacy in deterring infections; however, these methods employ the addition of mutagenic and potentially carcinogenic chemicals that alter the genetic makeup of the microbes. Residual amounts of these chemicals can remain within the transfusion product and then be transfused. In some cases, these chemicals may interact with the product itself, potentially changing its character. The main objective of this Phase I is to develop a bactericide that will address the above challenges. This technology provides an opportunity for better management of the platelet supply affecting millions of Americans annually, specifically for preventing bacterial related infections and sepsis through transfusion of contaminated platelets. The economic impact is also enormous considering the market size and associated savings from prolonging platelet shelf life and improving infection prevention. Once developed, the product can also be expanded for use with other blood product components and other medical sterilization applications such as water sterilization, infected surgical incisions, trauma and burn wounds, etc.

描述（由申请人提供）：本I期项目的目的是证明将众所周知且公认的抗菌金属银化合物与磁性纳米颗粒结合的可行性，并对其在细胞血液制品（如血小板）中的细菌灭活效果进行初步评价。Lynntech与M.D.德克萨斯州休斯顿的安德森癌症中心和宾厄姆顿的纽约大学将合成这些银涂层的磁性纳米颗粒（Ag-MP），这些纳米颗粒可以在细菌灭活过程后从血小板中完全回收。我们对细菌掺入的血小板和肉汤的初步数据表明，革兰氏阳性菌和阴性菌以及需氧菌和厌氧菌都可以灭活。根据国家血液数据资源中心的数据，美国每年约有1390万单位的全血捐献。血液制品的市场规模超过100亿美元，而且还在不断增长。全世界每年有超过9000万单位的血液捐献，因此，对提高血液制品安全性的方法的需求确实非常重要。与预防感染节省有关的经济影响也是巨大的（当病例被视为医院感染时，估计每年的费用从2.96亿美元到23亿美元不等）。血小板在现代医学中非常重要;然而，它们非常容易受到细菌污染，并且它们的保质期很短。血小板的细菌污染是输血传播感染的流动性和死亡率的主要原因。据估计，血小板的细菌污染率发生频率为1：2，000 - 1：3，000血小板单位。接受细菌污染的血小板的风险比HIV、B和C型肝炎以及人T细胞白血病（HTLV I/II）病毒的输血相关感染的合并风险高50至250倍。已经开发了新的化合物来对抗血液成分中的微生物污染，并且在阻止感染方面显示出轻微的功效;然而，这些方法使用了改变微生物的遗传组成的致突变和潜在致癌化学物质。这些化学物质的残留量可以保留在输血产品中，然后进行输血。在某些情况下，这些化学品可能与产品本身相互作用，可能会改变其特性。第一阶段的主要目标是开发一个可应对上述挑战的可持续发展战略。这项技术为更好地管理每年影响数百万美国人的血小板供应提供了机会，特别是通过输注受污染的血小板来预防细菌相关感染和败血症。考虑到市场规模和延长血小板保质期和改善感染预防的相关节省，经济影响也是巨大的。一旦开发出来，该产品还可以扩展用于其他血液制品成分和其他医疗灭菌应用，如水灭菌、感染的手术切口、创伤和烧伤等。

项目成果

Bacterial inactivation using silver-coated magnetic nanoparticles as functional antimicrobial agents.

• DOI: 10.1021/ac202164p
• 发表时间: 2011-11-15
• 期刊: ANALYTICAL CHEMISTRY
• 影响因子: 7.4
• 作者: Wang, Lingyan;Luo, Jin;Shan, Shiyao;Crew, Elizabeth;Yin, Jun;Zhong, Chuan-Jian;Wallek, Brandi;Wong, Season S. S.
• 通讯作者: Wong, Season S. S.